The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy.
 
Takeshi Kato
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma
 
Hideaki Bando
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Sysmex; Sysmex; Sysmex; Sysmex
 
Yuichiro Tsukada
No Relationships to Disclose
 
Koji Inamori
No Relationships to Disclose
 
Mamoru Uemura
No Relationships to Disclose
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Asahi Kasei; Asahi Kasei; Asahi Kasei; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly; Lilly; Lilly; Lilly; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Medical Review Co., Ltd.; Merck; Merck; Merck; Merck; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma; Moroo Co.; Moroo Co.; Moroo Co.; Moroo Co.; Nipro Corporation; Nipro Corporation; Nipro Corporation; Nipro Corporation; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Otsuka; Otsuka; Otsuka; Otsuka; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Shiseido; Shiseido; Shiseido; Shiseido; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Research Funding - A2 Healthcare; A2 Healthcare; A2 Healthcare; A2 Healthcare; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Eisai; Eisai; Eisai; Eisai; Incyte; Incyte; Incyte; Incyte; IQvia; IQvia; IQvia; IQvia; Mediscience Planning; Mediscience Planning; Mediscience Planning; Mediscience Planning; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; NanoCarrier; NanoCarrier; NanoCarrier; NanoCarrier; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Parexel International Corporation.; Parexel International Corporation.; Parexel International Corporation.; Parexel International Corporation.; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Sanofi/Aventis; Shionogi; Shionogi; Shionogi; Shionogi; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sumitomo Dainippon; Sysmex; Sysmex; Sysmex; Sysmex; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Shigenori Homma
No Relationships to Disclose
 
Daisuke Kotani
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Takeda; Takeda; Takeda; Takeda
Consulting or Advisory Role - Merck Serono; Merck Serono; Merck Serono; Merck Serono
 
Shota Fukuoka
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst)
 
Takeshi Sasaki
No Relationships to Disclose
 
Yuji Nishizawa
No Relationships to Disclose
 
Naoki Nakamura
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson; Johnson & Johnson
 
Motohiro Kojima
No Relationships to Disclose
 
Yosuke Togashi
No Relationships to Disclose
 
Akihiro Sato
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Aspyerian Therapeutics (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pentax Medical Devices; Pentax Medical Devices; Pentax Medical Devices; Pentax Medical Devices; Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Hiroyoshi Nishikawa
Honoraria - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Bristol-Myers Squibb Japan; Celgene; Celgene; Celgene; Celgene; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Eisai; Eisai; Eisai; Eisai; MSD K.K; MSD K.K; MSD K.K; MSD K.K; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; BD Biosciences; BD Biosciences; BD Biosciences; BD Biosciences; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; Celgene; Celgene; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; KYOWA HAKKO BIO; KYOWA HAKKO BIO; KYOWA HAKKO BIO; KYOWA HAKKO BIO; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sumitomo Group; Sysmex; Sysmex; Sysmex; Sysmex; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Zenyaku Kogyo; Zenyaku Kogyo; Zenyaku Kogyo; Zenyaku Kogyo
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst)
 
Masaaki Ito
No Relationships to Disclose